Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIP152 Monotherapy and Combination with Pembrolizumab in Advanced Cancer
NCT02635672Phase 1Completed
- Sponsor
- Vincerx
- Start
- Feb 2016
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of enitociclib in solid tumor and non-Hodgkin lymphoma (NHL) (4 arms), sponsored by Vincerx. Primary endpoints: Incidence of Dose Limiting Toxicity, Maximum Observed Drug Concentration and 3 more. Started Feb 2016; status: completed.
02
Drugs
enitociclib
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02635672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02635672.